To: | Alkermes Pharma Ireland Limited (IPDocketing@foley.com) |
Subject: | U.S. Trademark Application Serial No. 88489837 - LYBALVI - 029318-2810 |
Sent: | September 18, 2019 12:35:14 PM |
Sent As: | ecom128@uspto.gov |
Attachments: |
United States Patent and Trademark Office (USPTO)
Office Action (Official Letter) About Applicant’s Trademark Application
U.S. Application Serial No. 88489837
Mark: LYBALVI
|
|
Correspondence Address: |
|
Applicant: Alkermes Pharma Ireland Limited
|
|
Reference/Docket No. 029318-2810
Correspondence Email Address: |
|
EXAMINER’S AMENDMENT
Issue date: September 18, 2019
USPTO database searched; no conflicting marks found. The trademark examining attorney searched the USPTO database of registered and pending marks and found no conflicting marks that would bar registration under Trademark Act Section 2(d). 15 U.S.C. §1052(d); TMEP §704.02.
Application has been amended as shown below. As agreed to by Norm J. Rich on September 17, 2019 the examining attorney has amended the application as shown below. Please notify the examining attorney immediately of any objections. TMEP §707. Otherwise, no response is required. Id. In addition, applicant is advised that amendments to the goods and/or services are permitted only if they clarify or limit them; amendments that add to or broaden the scope of the goods and/or services are not permitted. 37 C.F.R. §2.71(a).
AMENDED DESCRIPTION OF THE MARK
The following description of the mark replaces the current description of record:
“The mark consists of the word “LYBALVI” in blue below a curved two-paneled ribbon design, the bottom portion of the ribbon being blue and the top portion being metallic copper.”
See 37 C.F.R. §§2.37, 2.72; TMEP §§808 et seq.
Arriola, Kimberly
/Kimberly C. Arriola/
Attorney Advisor
Law Office 128
(571) 270-7984
kimberly.arriola@uspto.gov